Abbott Diabetes Care, Inc.: FDA filings under this applicant name
FDA lists 39 510(k) clearances under 2 spellings of the applicant name “Abbott Diabetes Care, Inc.” (first 2000, latest 2024), plus 2 PMA and 1 De Novo decisions, across 10 product codes in 1 review panel. Median 510(k) review time under this name: 164 days. Since 2017 the median was 178 days, against 191 days for all cleared 510(k)s in the same product codes. Related companies, subsidiaries and acquired businesses that file under other applicant names are counted on their own pages, not here.
Caduvo groups this applicant name under Abbott, based on public ownership records.
510(k) clearances per year
| Year | Clearances | Median review days |
|---|---|---|
| 2012 | 1 | 31 |
| 2013 | 2 | 151 |
| 2014 | 1 | 228 |
| 2015 | 1 | 356 |
| 2016 | 1 | 92 |
| 2017 | 1 | 91 |
| 2018 | 0 | — |
| 2019 | 0 | — |
| 2020 | 1 | 190 |
| 2021 | 3 | 237 |
| 2022 | 2 | 240 |
| 2023 | 3 | 150 |
| 2024 | 2 | 178 |
| 2025 | 0 | — |
| 2026 | 0 | — |
Review time against the same product codes
Since 2017, 510(k)s cleared under the name Abbott Diabetes Care, Inc. took a median 178 days from FDA receipt to decision. All cleared 510(k)s in the same product codes over the same years took a median 191 days.
Top product codes
| Product code | Device | Submissions | 510(k) clearances |
|---|---|---|---|
| NBW | System, Test, Blood Glucose, Over The Counter | 19 | 19 |
| QLG | Integrated Continuous Glucose Monitoring System, Factory Calibrated, Not For Use With Automated Insulin Delivery Systems | 7 | 7 |
| LFR | Glucose Dehydrogenase, Glucose | 5 | 5 |
| LZG | Pump, Infusion, Insulin | 3 | 3 |
| QBJ | Integrated Continuous Glucose Monitoring System, Factory Calibrated | 3 | 3 |
| JIN | Nitroprusside, Ketones (Urinary, Non-Quant.) | 1 | 1 |
| MDS | Sensor, Glucose, Invasive | 1 | 0 |
| PZE | Sensor, Glucose, Invasive, Non-Adjunctive, Factory-Calibrated, User-Initiated | 1 | 0 |
| SBH | Integrated Continuous Glucose Monitor For Non-Intensive Glucose Management, Over-The-Counter | 1 | 1 |
| SJD | Integrated Continuous Glucose Ketone Monitoring System | 1 | 0 |
Review panels
- Clinical Chemistry (42)
Most recent Abbott Diabetes Care, Inc. 510(k) clearances
| 510(k) | Device | Product code | Decision date | Review days |
|---|---|---|---|---|
| K233861 | Libre Rio Continuous Glucose Monitoring System | SBH | 2024-06-07 | 184 |
| K233537 | FreeStyle Libre 3 Continuous Glucose Monitoring System; FreeStyle Libre 2 Flash Glucose Monitoring System | QBJ | 2024-04-23 | 172 |
| K223435 | FreeStyle Libre 3 Continuous Glucose Monitoring System; FreeStyle Libre 2 Flash Glucose Monitoring System | QBJ | 2023-04-13 | 150 |
| K222447 | FreeStyle Libre 2 Flash Glucose Monitoring System; Freestyle Libre 3 Continuous Glucose Monitoring System | QBJ | 2023-03-03 | 200 |
| K223537 | FreeStyle Libre 2 System, FreeStyle Libre 3 System | QLG | 2023-02-21 | 90 |
| K213996 | FreeStyle Libre 3 Continuous Glucose Monitoring System | QLG | 2022-05-26 | 157 |
| K212132 | FreeStyle Libre 3 Continuous Glucose Monitoring System | QLG | 2022-05-26 | 322 |
| K210943 | FreeStyle Libre 2 Flash Glucose Monitoring System (with FreeStyle Libre 2 App) | QLG | 2021-11-22 | 237 |
| K211102 | FreeStyle Libre 2 Flash Glucose Monitoring System | QLG | 2021-08-11 | 120 |
| K201761 | FreeStyle Libre 2 Flash Glucose Monitoring System (with FreeStyle Libre 2 App) | QLG | 2021-07-30 | 396 |
29 earlier clearances. See the full list in Caduvo.
PMA and De Novo decisions
| Number | Pathway | Device | Decision date |
|---|---|---|---|
| DEN250049 | De Novo | Integrated Continuous Glucose Ketone Monitoring System | 2026-08-25 |
| P160030 | PMA | Freestyle Libre Flash Glucose Monitoring System | 2017-09-27 |
| P150021 | PMA | FREESTYLE LIBRE PRO FLASH GLUCOSE MONITORING SYSTEM | 2016-09-23 |
Recalls
57 product recalls in 21 recall events; 10 initiated in the last five years. Most recent: 2025-11-24.
2 product recalls in 1 recall event filed under other recalling-firm names cite a 510(k) or PMA held under this applicant name; 0 initiated in the last five years. Most often: Cardinal Health Inc. (2).
These recall records list the clearance number, so the device was cleared under this name. The recalling firm may be the same company under another spelling, a company that acquired the product line, a relabeler or a contract manufacturer. They are not added to the count above.
Recalling firms are matched to this applicant name by name only (same normalization), so related entities that recall under another name are not counted. A recall count says nothing about how safe one company's devices are compared with another's.
Device clinical trials
An industry sponsor named Abbott Diabetes Care, Inc. is the lead sponsor of 42 device studies on ClinicalTrials.gov (5 active or recruiting). Most recent:
- NCT07739342: Evaluating the Occurrence of DKA in People With Type I Diabetes (Not yet recruiting, started 2026-09)
- NCT06921902: Glycemic Metrics and Patterns in People With and Without Prediabetes (Recruiting, started 2025-02-28)
- NCT06668935: Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring (Recruiting, started 2024-10-24)
- NCT06268808: Initiation of Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin, in Italy (Completed, started 2024-07-19)
- NCT06268821: Effect on HbA1c of the Initiation of CGM in Adults With Type 2 Diabetes Treated With Basal Insulin in Finland (Terminated, started 2024-04-02)
Parent company SEC filings
ABBOTT LABORATORIES (ABT): EDGAR filings, CIK 1800. Caduvo groups Abbott Diabetes Care, Inc. under Abbott; the parent's SEC registrant is entered by hand for the group, not matched by name.
Related HCPCS codes
HCPCS Level II codes whose descriptors match the device names of the product codes filed under Abbott Diabetes Care, Inc. (a text match, not an official crosswalk):
- A4220 — Refill kit for implantable infusion pump (via LZG)
- E0786 — Implantable programmable infusion pump, replacement (excludes implantable intraspinal catheter) (via LZG)
FDA spellings included
FDA records this applicant under 2 spellings (case, punctuation and legal-suffix variants of one name); this page adds them up. Filings per spelling:
- Abbott Diabetes Care, Inc. (39)
- Abbott Diabetes Care (3)
Other FDA applicant names starting with the same word
FDA records these as separate applicants. Some may belong to the same corporate group and some may not; their filings are not included in the counts above.
- Abbott Laboratories (890 510(k)s)
- ABBOTT MEDICAL (60 510(k)s)
- Abbott Vascular (50 510(k)s)
- Abbott Diagnostics (28 510(k)s)
- Abbott Point of Care, Inc. (22 510(k)s)
- Abbott Molecular, Inc. (18 510(k)s)
- Abbott Mfg., Inc. (14 510(k)s)
- Abbott Medical Optics, Inc. (13 510(k)s)
- Abbott (13 510(k)s)
- Abbott Spine, Inc. (13 510(k)s)
- Abbott Ireland Diagnostics Division (8 510(k)s)
- Abbott Diagnostics Scarborough, Inc. (7 510(k)s)
Frequently asked questions
How many FDA 510(k) clearances are listed under Abbott Diabetes Care, Inc.?
FDA lists 39 510(k) clearances under 2 spellings of the applicant name “Abbott Diabetes Care, Inc.” (first 2000, latest 2024), plus 2 PMA and 1 De Novo decisions, across 10 product codes in 1 review panel. Filings under other applicant names, such as subsidiaries, are not included.
How long has FDA taken to clear 510(k)s filed by Abbott Diabetes Care, Inc.?
The median time from FDA receipt to decision across 510(k)s cleared under the name Abbott Diabetes Care, Inc. is 164 days. Since 2017: 178 days, versus 191 days for all cleared 510(k)s in the same product codes.
Which FDA product codes appear under Abbott Diabetes Care, Inc.?
The most frequent FDA product codes under this applicant name are NBW (System, Test, Blood Glucose, Over The Counter, 19); QLG (Integrated Continuous Glucose Monitoring System, Factory Calibrated, Not For Use With Automated Insulin Delivery Systems, 7); LFR (Glucose Dehydrogenase, Glucose, 5).
Next steps
- See all 39 Abbott Diabetes Care, Inc. clearances with predicates and recalls
- Run predicate analysis for product code NBW, Abbott Diabetes Care, Inc.'s most frequent
Compiled by Caduvo from public U.S. government records. Counts cover filings under the applicant names shown on this page only. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA or any other agency, or by the companies named. Not regulatory advice. Report an error in this data. Data and corrections policy.